App Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
App Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications. [1]
Mutations in the Amyloid Precursor Protein (APP) gene cause autosomal dominant familial Alzheimer's disease, providing critical insights into amyloid-beta pathogenesis. [2]
APP is a transmembrane glycoprotein with diverse physiological functions: [3]
APP is cleaved by three secretases: [4]
| Secretase | Cleavage Site | Products |
|---|---|---|
| α-secretase | Aβ domain (Residue 16) | sAPPα, CTFα (non-amyloidogenic) |
| β-secretase (BACE1) | N-terminus of Aβ | sAPPβ, CTFβ |
| γ-secretase | Transmembrane domain | Aβ peptides (Aβ40, Aβ42) |
APP mutations cause AD through two primary mechanisms:
Individuals with Down syndrome have three copies of APP (gene dosage effect):
BACE inhibitors: Block Aβ production at source
γ-secretase modulators: Shift cleavage toward shorter Aβ peptides
Anti-Aβ antibodies: Clear existing plaques
| Mutation | Therapeutic Implication |
|---|---|
| Swedish | BACE inhibitor responsive |
| Arctic | Anti-aggregation drugs |
| Dutch/Iowa | CAA-focused approaches |
| All | Anti-Aβ immunotherapies |
App Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of App Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
Mapping dementia research in Morocco: A scoping review of epidemiological, genetic, and therapeutic evidence. ↩︎
Molecular Complexities of Dementia: PAISA Mutations and Targeting TAF2N as Therapeutic Avenues. ↩︎
Compromised synaptic signal from prefrontal cortex to mediodorsal thalamus in Alzheimer's disease models and its rescue by kinase inhibitors. ↩︎
Differences in hearing across the lifespan in two strains of Alzheimer's mouse models as measured using behavioral and physiological techniques. ↩︎